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Objectives: To determine the association between embB mutations and drug resistance, and to further inves-
tigate the mechanism of embB mutations involved in the development of ethambutol and multidrug resistance
in Mycobacterium tuberculosis.
Methods: One hundred and thirty-eight multidrug-resistant clinical M. tuberculosis isolates, including 86 etham-
butol-resistant and 52 ethambutol-susceptible strains, were analysed to characterize mutations within the
entire coding region of the embB gene. Moreover, a two-step genotyping was performed to identify the
genetic lineage.
Results: In total, 27 embB mutation types were detected in 19 distinct codons. Though a strong association
was observed between embB mutations and ethambutol resistance, 19.2% of embB306 mutants and 11.5%
of embB406 or embB497 mutants were ethambutol susceptible. Among 39 ethambutol-resistant strains
without embB306 mutations, 51.3% harboured mutations at codons 406 or 497. Particularly, three pairs of iso-
lates with identical embB mutations and genotyping features were identiﬁed with variant ethambutol suscep-
tibility. Among 77 isoniazid, rifampicin, streptomycin and ethambutol quadruple drug-resistant isolates, 89.6%
carried embB mutations and 83.1% could be identiﬁed by detecting 10 embB mutations.
Conclusions: Our results suggest embB mutations alone are not sufﬁcient for the development of full resistance
to ethambutol in M. tuberculosis and mutations other than embB are also needed. Our study conﬁrms the
importance of mutations at embB406 and embB497 as hotspots, in addition to embB306, for detecting etham-
butol resistance. Ten selected mutations of embB, covered by a short PCR product, can be used as candidate
markers for the prediction of quadruple resistance to isoniazid, rifampicin, streptomycin and ethambutol.
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Introduction
Multidrug-resistant (MDR) tuberculosis (TB) has an estimated
4.8% prevalence worldwide and poses a serious threat to
global public health.
1 In China, the signiﬁcantly high (9.3%)
prevalence of MDR-TB makes the prevention and control of
tuberculosis especially challenging.
2 The rapid and reliable detec-
tion of drug resistance is critical for optimizing treatment regi-
mens and for preventing the spread of tuberculosis.
Ethambutol, which is an essential ﬁrst-line drug in tuberculo-
sis treatment, plays an important role in the chemotherapy of
drug-resistant TB.
3 Ethambutol inhibits mycobacterial arabinosyl
transferases encoded by the embCAB operon, which includes
three genes (embC, embA and embB). Amino acid substitutions
encoded by embB are observed in non-tuberculous mycobacteria
with intrinsic resistance to ethambutol.
4 Exchanging wild-type
embB306, embB497 and embB406 with mutant codons
increases the ethambutol minimal inhibition concentrations
(MICs) of Mycobacterium tuberculosis.
5–7 Mutations at embB320
and embB324,
5,7 as well as mutations at embB397, embB445,
embB1024 and embC13, have also been found to be associated
with ethambutol resistance.
5
# The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.
org/licenses/by-nc/2.5),whichpermitsunrestrictednon-commercialuse,distribution,andreproductioninanymedium,providedtheoriginalwork
is properly cited.
J Antimicrob Chemother 2011; 66: 2240–2247
doi:10.1093/jac/dkr284 Advance Access publication 21 July 2011
2240The most commonly detected point mutation in ethambutol-
resistant clinical strains of M. tuberculosis is in the embB gene at
codon 306, which occurs in 30%–69% of ethambutol-resistant
clinical strains.
4,8–11 Initial studies indicated that the embB306
mutations were only observed in ethambutol-resistant strains
and led to the proposal that the embB306 locus be considered
as a diagnostic marker for ethambutol resistance.
10 However,
the detection of embB306 from ethambutol-susceptible clinical
isolates questions the validity of this assertion.
12–15 Mokrousov
et al.
14 ﬁrst described this phenomenon as a genuine discrepancy
between genotypic and phenotypic tests, and noticed that
embB306 mutations in ethambutol-susceptible isolates were
limited to the isolates already resistant to other drugs. Based on
a study of 1020 clinical isolates, Hazbon et al.
12 suggested that
the embB306 mutation is associated with broad drug resistance
rather than ethambutol resistance per se. Shen et al.
15 also pro-
posedthe embB306locusas acandidate markerforthe detection
of MDR and extensively drug-resistant M. tuberculosis isolates.
Although the association between embB306 mutation and
ethambutol resistance or broad drug resistance has been
observed in several groups’ studies with both clinical or laborator-
ial isolates,
5,6,9,16,17the exact role embB306 mutations play in the
development of ethambutol resistance and multidrug resistance
in M. tuberculosis is not fully understood. Mutations in embB
other than embB306 were also detected in these studies, but
the contribution of such mutationsto the development of etham-
butol resistance is similarly not clear. It is believed that variant
genetic alterations that accumulate in epidemic M. tuberculosis
leadtothedevelopmentofdrugresistance,
18–20includingetham-
butol resistance,
5 but not much evidence has been obtained from
studies of clinical isolates.
Therefore, to further investigate the mechanism of embB
mutations in the development of drug resistance and to evaluate
the association between embB mutations and drug resistance,
including ethambutol, multidrug and broad drug resistance, a
relatively large population of MDR-TB isolated from Henan pro-
vince, China was examined. In the present study, we character-
ized the mutations of the embB complete coding sequence and
documented the variable number tandem repeat of mycobacter-
ial interspersed repetitive units (MIRU-VNTR) genotypes of this
MDR-TB population, to further analyse the mechanism under-
lying the development of ethambutol drug resistance in clinical
M. tuberculosis isolates.
Materials and methods
M. tuberculosis clinical strains
One hundred and ﬁfty MDR-TB strains were collected by sequentially
screening 1605 clinical M. tuberculosis strains isolated from patients
from Henan province in 2007–09. Meanwhile, 22 pan-susceptible strains
were collected from the same location to be used as controls in this study.
Drug susceptibility testing (DST)
DST to four ﬁrst-line antituberculosis drugs was performed in the
Tuberculosis Reference Laboratory at Henan Provincial Centers for
Disease Control and Prevention, China. The Lo ¨wenstein–Jensen (LJ) pro-
portion method, recommended by WHO/International Union Against
Tuberculosis and Lung Disease (IUATLD), was used to perform
DST with the following critical drug concentrations: 0.2 mg/L isoniazid;
40.0 mg/L rifampicin; 2.0 mg/L ethambutol; and 4.0 mg/L
streptomycin.
21,22
RD105 deletion-targeted multiplex PCR (DTM-PCR)
and MIRU-VNTR genotyping
DTM-PCR was performed to identify the Beijing family strains.
23 A
China-speciﬁed MIRU-VNTR genotyping method (VNTR-7) was performed
on all MDR-TB isolates with seven VNTR loci in this study, and additional
nine VNTR loci (VNTR-9) was applied to the isolates with identical ﬁrst
seven VNTR loci.
24,25 Samples with more than one band in the PCR
product on any VNTR locus were considered as mixed strains and
excluded from the studied population. The VNTR genotyping data, trans-
formed into a distance matrix on the web site MIRU-VNTRplus (http
://www.miru-vntrplus.org) by default setting, were treated as categorical
variables and the phylogenetic analysis of the distance data was con-
ducted using MEGA version 4.
26,27
PCR ampliﬁcation, sequencing and data analysis
The full-length embB gene coding region of the studied strains was
ampliﬁed with three overlapped fragments. Chromosomal DNA was
extracted using the boiling method.
28 Phusion
w Hot Start High-Fidelity
DNA Polymerase (Finnzymes, Finland), an ultrahigh-ﬁdelity DNA poly-
merase, was used for the ampliﬁcation. The primers synthesized by
Sangon Biochemical for DNA ampliﬁcation were: embB1-1 (5′-
TCGACGATCGCCACGTACCT-3′) and embB1-2 (5′-CAGCAGCAGCCAGCA
CACTA-3′); embB2-1 (5′-TATTCGGCTT CTGCTCTGG-3′) and embB2-2
(5′-CACACCGTAGCTGGAGACAT-3′); and embB3-1 (5′-GTTCCTGGC
GGCGTTATTCT-3′) and embB3-2 (5′-AGCCTG ACGCTATGGACCAA-3′). The
sequencing primers were embB(S)1 (5′-CGTCCTTGCCTTGCTTGGGT-3′)
and embB(S)3 (5′-GCGTGGTATCTCCTGCCTAAG-3′); other sequencing
primers were the same as embB1-2, embB2-1, embB2-2 and
embB3-1. PCR products were sequenced by Sinogenomax Co. Ltd.
Sequence data were assembled by Seqman pro (version 7.1, DNAstar
Lasergene), and mutations were determined by comparing with the
H37Rv sequence of embB from Tuberculist (http://genolist.pasteur.fr/
TubercuList/) and the GenBank database (http://www.ncbi.nih.gov/
gene). The frequency calculation and association analysis were per-
formed using SPSS for Windows
w (version 10.0, SPSS, Inc., USA).
Results and discussion
General proﬁle of genotyping, drug resistance
and embB mutations
Twelve isolates (8%) of the primary study population, which were
identiﬁed as a mixture of different individual MDR-TB strains by a
two-step genotyping method of VNTR-7 and VNTR-9, were not
included in the following analysis. In total, 138 MDR isolates
included in the study showed 116 unique and 11 clustered gen-
otyping patterns based on VNTR-7 genotyping (Figure 1a). Most
of the MDR isolates (95%, 131/138) were identiﬁed as Beijing
family M. tuberculosis strains by DTM-PCR. Among the 138 clinical
MDR-TB isolates, 9 presented no additional resistance (isoniazid/
rifampicin resistant), 43 were isoniazid/rifampicin/streptomycin
resistant, 9 were isoniazid/rifampicin/ethambutol resistant and
77 were isoniazid/rifampicin/ethambutol/streptomycin resistant.
There were 86 ethambutol-resistant and 52 ethambutol-
susceptible isolates.
One hundred and thirty-eight MDR-TB strains were screened
for embB mutations. A total of 119 embB mutations representing
embB mutations in MDR-TB
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ID VNTR-9 genotyping
55 1    2    3    3     2    5    4     2    4
99 1    2    3    3     4    5    4     2    4
100 1    2    3    3     4    5    4     2    4
21 3    2    3    3     3    6    1     1    4
108 3    2    3    3     3    6    1     1    4
9 3    2    3    3     2    5    4     2    4
129 3    2    3    3     2    5    4     2    4
1    2    3    3     2    5    4     2    4 92
VNTR-9
result
Amino acid change
Met306Ile ATGÆATT
ATGÆATT
ATGÆATA
ATGÆATA
CAGÆCGG
CAGÆCGG
CAGÆCGG
CAGÆCGG
GGCÆGCC
GGCÆGAC
ATGÆATA, CAGÆCCG
ATGÆATA
ATGÆATT
ATGÆATA
ATGÆGTG
ATGÆGTG
ATGÆGTG
ATGÆCTG
ATGÆCTG
ATGÆGTG
ATGÆATA
ATGÆATC
ATGÆATC
ATGÆGTG, GGCÆGCC
Met306Ile
Met306Ile
Met306Ile
Gln497Arg
Gln497Arg
Gln497Arg
Gln497Arg
Gly406Ala
Gly406Asp
Met306Ile
Met306Ile
Met306Ile
Met306Ile
Met306Ile
Met306Ile
Met306Leu
Met306Leu
Met306Val
Met306Val
Met306Val
Met306Val
Met306Ile, Gln497Pro
Met306Val, Gly406Ala
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Nucleotide change Drug
resistance
HRS
HRS
HRS
HRS
HRS
HRS
HRS
HRS
HRS
HRE
HRE
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HRES
HR
HRES
HRES
HRE
HRE
HRE
HR
95
54
106
102
36
8
122
22
55
92
68
91
63
147
53
116
Cluster A
6
146
7
40
148
97
113
37
125
27
84
26
93
25
80
47
67
43
94
82
52
66
124
128
130
123
135
44
103
21
108
79
42
121
30
75
111
74
9
129
69
70
59
132
140
62
4
60
20
41
71
81
61
127
16
29
56
73
65
110
18
32
35
112
149
119
107
50
34
104
51
134
101
58
117
83
49
88
48
76
38
31
72
86
28
141
24
145
5
10
19
142
90
96
105
150
126
11
78
77
114
17
87
23
131
139
45
46
89
85
118
13
14
12
98
109
39
138
0.1
99
100
64
C
C
C
C
C
C
C
C
69 2    2    3    3     2    5    4     2    4 U
70 5    2    2    3     2    5    4     1    4 U
16 4    2    3    3     2    5    4     2    4 U
29 3    2    3    3     2    5    4     2    2 U
149 3    2    3    3     2    5    4     0    5 U
119 3    2    3    3     2    5    4     2    4 U
107 3    2    3    3     2    4    4     2    4 U
50 2    2    3    3     2    5    4     2    4 U
34 2    2    3    3     2    5    4     1    4 U
145 3    2    3    3     2    5    4     2    4 U
5 2    2    3    3     2    5    4     2    4 U
150 3    2    3    3     2    5    4     2    4 U
126 3    2    3    3     2    5    2     2    4 U
98 3    2    3    3     2    5    4     2    4 U
109 3    2    3    3     2    5    3     2    4 U
96 2    2    3    3     2    5    4     2    4
105 2    2    3    3     2    5    4     2    4
23 3    2    3    3     2    5    4     2    4
131 3    2    3    3     2    5    4     2    4
86 3    2    3    3     2    5    4     2    4
28 3    2    3    3     2    5    4     2    4
65 3    2    3    3     2    5    4     2    4
110 3    2    3    3     2    5    4     2    4
(a) (b)
0.1
(c)
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224227 mutations types were detected in 19 distinct codons, includ-
ing 4 synonymous mutation types at codons 304, 424, 534 and
539 (Table 1). Ninety-four mutations were detected in 86
ethambutol-resistant MDR-TB strains. Twenty-ﬁve mutations
were detected in 52 ethambutol-susceptible MDR-TB strains. Of
the 138 MDR-TB isolates studied, 38 (27.5%) showed wild-type
embB sequences while 100 (72.5%) showed mutated sequences
(Table 2).
Overall, 16 isolates carried more than one mutation in the
entire coding region of embB, including 7 isolates with two non-
synonymous embB mutations (Table 2). There were three isolates
that carried triple embB mutations. Thirteen isolates were
detected to have double embB mutations, of which 5 isolates
carried two non-synonymous mutations. Among the seven iso-
lates carrying two non-synonymous embB mutations, six were
resistant to ethambutol (isoniazid/rifampicin/ethambutol resist-
ant or isoniazid/rifampicin/ethambutol/streptomycin resistant).
Particularly, among those ethambutol-resistant isolates with
multiple mutations, three isolates contained mutation combi-
nations involving codons 306, 406 and 497 (embB306 plus
embB406; embB306 plus embB497), which has not been docu-
mented in previous studies.
8,10,29
Characteristics of embB306 mutation
One of the major mutations was embB306, accounting for the
highest proportion of all mutations detected in our study.
Altogether, 41.3% (57/138) of MDR-TB isolates carried the
embB306 mutation. The proportion of embB306 mutants
among ethambutol-resistant MDR strains (54.7%, 47/86) was
Table 1. Mutation pattern of the embB gene in isolates with different phenotypes
Locus
Number of mutations
ethambutol-susceptible MDR ethambutol-resistant MDR
isoniazid/
rifampicin
isoniazid/rifampicin/
streptomycin
total
ethambutol
susceptible
isoniazid/
rifampicin/
ethambutol
isoniazid/rifampicin/
ethambutol/
streptomycin
total
ethambutol
resistant pan-susceptible
embB306 3 7 10 4 43 47 0
embB497 3 3 3 13 16 0
embB406 3 3 1 6 7 0
embB354 2 2 2 2 0
embB534
a 1 1 3 8 11 1
embB304
a 01 1 0
embB328 0 1 1 0
embB330 0 1 1 0
embB424
a 01 1 0
embB439 0 1 1 0
embB469 1 1 0 0
embB508 1 1 0 0
embB539
a 01 1 0
embB627 0 1 2 3 0
embB651 1 1 0 0
embB667 1 1 0 0
embB1000 0 1 1 0
embB1002 0 1 1 0
embB1024 2 2 0 0
Total 3 22 25 13 81 94 1
aSynonymous mutations.
Figure 1. Phylogenetic analysis of MDR-TB isolates, and characteristics of VNTR-9 genotyping, embB mutations and drug resistance patterns of
isolates with the clustered VNTR-7 genotypes. (a) Phylogenetic map generated by the neighbour-joining (NJ) method, based on VNTR-7
genotyping data of 138 MDR-TB isolates. Numbers indicate strain ID. Filled circles indicate ethambutol-susceptible embB306 mutants, while open
circles indicate ethambutol-resistant counterparts. Filled squares indicate ethambutol-susceptible embB497 mutants, while open squares indicate
ethambutol-resistant embB497 counterparts. Filled triangles indicate ethambutol-susceptible embB406 mutants. (b) VNTR-9 genotypes, embB
mutations and drug resistance patterns of isolates showing the clustered VNTR-7 genotypes. Blocks highlight three pairs of isolates with identical
VNTR-16 genotypes and embB mutations, but opposite ethambutol resistance. C indicates isolates with identical VNTR-9 genotyping patterns. U
indicates isolates with unique VNTR-9 genotyping patterns. H, isoniazid; R, rifampicin; E, ethambutol; S, streptomycin. (c) Radial NJ phylogeny
based on VNTR-7 genotyping data of MDR-TB isolates, which shows the genetic background of six EmbB Met306Leu mutants. Filled circles
represent strains with a Met Leu amino acid substitution.
embB mutations in MDR-TB
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JACmuch higher than in the ethambutol-susceptible MDR strains
(19.2%, 10/52). While the association between embB306
mutation and ethambutol resistance is statistically signiﬁcant
(odds ratio¼5.1, x
2¼16.7, P,0.0001), our data suggest that
embB306 is not the sole causative mutation of ethambutol
resistance, but is a sensitive candidate marker for ethambutol
resistance analysis. Our ﬁnding that embB306 mutations exist
in both ethambutol-resistant and -susceptible clinical M. tubercu-
losis isolates differs from the work of Plinke et al.,
9 in which they
showed no embB306 mutation in ethambutol-susceptible MDR
strains, but agrees with the observations of others.
12,15 One
possible explanation for this inconsistency between phenotypic
and genotypic testing results is that embB306 mutations
confer M. tuberculosis variable ethambutol MICs and clinical
strains with low to moderate levels of resistance may readily
show opposite ethambutol susceptibility results using different
testing methods.
6,16,17,30 The occurrence of the embB306
mutations has been compared in different lineages and geno-
types to identify the association between mutations and
genetic structures.
12,14 However, in MDR strains, it is not well
addressed whether the genetic background contributes to the
levels of ethambutol resistance in embB306 mutants. In this
study, after locating the ethambutol-susceptible isolates with
embB306 mutations into the phylogenetic map, we found that
Table 2. Characteristics of embB mutants within the MDR-TB isolates
Locus Nucleotide change Amino acid change
No. of isolates
(percentage
of 138 MDR isolates)
embB306 atg Ctg Met Leu 46 (33.3)
atg Gtg Met Val
atg atA Met Ile
atg atC Met Ile
atg atT Met Ile
embB306 and embB534 atg atC and gac gaT Met Ile and Asp Asp 6 (4.3)
atg Gtg and gac gaT Met Val and Asp Asp
embB306 and embB354 G inserts between AT and gac gCc frameshift and Asp Ala 1 (0.7)
embB306 and embB406 atg Gtg and ggc gCc Met Val and Gly Ala 1 (0.7)
embB306 and embB424 atg Gtg and cgg cgA Met Val and Arg Arg 1 (0.7)
embB306 and embB497 and
embB304
atg Ctg and cag cCg and ctg Ttg Met Leu and Gln Pro and Leu Leu 1 (0.7)
embB306 and embB497 and
embB534
atg atA and cag cCg and gac gaT Met Ile and Gln Pro and Asp Asp 1 (0.7)
embB328 gat Tat Asp Tyr 1 (0.7)
embB330 ttc tCc Phe Ser 1 (0.7)
embB354 gac gCc Asp Ala 3 (2.2)
embB406 ggc Agc Gly Ser 8 (5.8)
ggc gAc Gly Asp
ggc gCc Gly Ala
embB406 and embB534 and
embB539
ggc gAc and gac gaT and cgg cgA Gly Asp and Asp Asp and Arg Arg 1 (0.7)
embB439 gca Aca Ala Thr 1 (0.7)
embB469 cgt cAt Arg His 1 (0.7)
embB497 cag cCg Gln Pro 15 (10.9)
cag cGg Gln Arg
embB497 and embB627 cag cGg and T inserts between CG Gln Arg and frameshift 1 (0.7)
embB497 and embB1024 cag cCg and gac Aac Gln Pro and Asp Asn 1 (0.7)
embB508 gtt Ttt Val Phe 1 (0.7)
embB534 gac gaT Asp Asp 2 (1.4)
embB534 and embB1000 gac gaT and atg aGg Met Arg 1 (0.7)
embB534 and embB1002 gac gaT and cac cGc His Arg 1 (0.7)
embB627 T inserts between CG frameshift 2 (1.4)
embB651 agc aCc Ser Thr 1 (0.7)
embB667 aca aAa Thr Lys 1 (0.7)
embB1024 gac Aac Asp Asn 1 (0.7)
Mutant isolates 100 (72.5)
Wild-type isolates 38 (27.5)
Shi et al.
2244although 80% (8/10) of ethambutol-susceptible embB306
mutants niched in a major cluster (indicated as ‘cluster A’ in
Figure 1a), the genetic background of these strains was diverse
and failed to identify an obvious relationship of any speciﬁc
genetic lineage with pheno-genotype discordance of embB306
mutants (Figure 1a). Interestingly, two pairs of embB306
mutants sharing identical VNTR-16 genotyping patterns but
with different ethambutol susceptibility for each paired isolates
clearly indicates that ethambutol resistance and susceptibility
can exist in clinical isolates with highly similar genetic back-
ground (Figure 1a). Different types of embB306 mutation have
been reported to affect the ethambutol MICs for M. tuberculosis
and the results of ethambutol susceptibility testing.
6,10,17
However, the pair 1 isolates (isolate 55 versus isolate 92) both
carried a single embB306 mutation (ATG ATT), of which
isolate 92 was ethambutol resistant and isolate 55 was etham-
butol susceptible. The pair 2 isolates (isolate 99 versus isolate
100) carried another single embB306 mutation (ATG ATA), of
which isolate 99 was ethambutol resistant while isolate 100
was ethambutol susceptible (Figure 1b). Thus, the pheno-
genotype discordance of embB306 mutation and ethambutol
resistance is not likely related to different types of embB306
mutation or multiple mutations of embB. In addition, this
ﬁnding is unlikely related to additional antibiotic resistances, as
observed between multidrug resistance and ethambutol resist-
ance,
15 because each of the paired isolates share identical ﬁrst-
line drug resistance patterns (isoniazid/rifampicin resistant for
pair 1 and isoniazid/rifampicin/streptomycin resistant for pair
2). The inconsistency between ethambutol DST results and
embB306 mutation is more likely related to other mutations
occurring outside the embB gene in the genome of these clinical
strains. Several previous works indicate that ethambutol resist-
ance is a multigene mutation process that requires mutations
in the embB gene and other currently unknown loci.
5,16 Our ﬁnd-
ings clearly suggest that the determinant of ethambutol resist-
ance may invoke more than one gene variation including embB
gene, and that concurrent mutations incident at different sites
of the bacterial genome are needed to confer overt ethambutol
resistance of M. tuberculosis.
Interestingly, the ATG CTG mutation at embB306, which was
associated with a higher ethambutol MIC and conferred a growth
advantage under sub-MICs of isoniazid or rifampicin,
6,10 was
detected in six strains with quadruple ﬁrst-line drug resistance
(isoniazid/rifampicin/ethambutol/streptomycin resistant) in our
study (Table S1, available as Supplementary data at JAC
Online) (Figure 1c).
Characteristics of embB497 and embB406 mutations
The major embB mutations detected in our isolates include not
only embB306, but embB497 and embB406 as well. Mutations
in embB497 were found in 16/86 (18.6%) ethambutol-resistant
strains and 3/52 (5.8%) ethambutol-susceptible strains. Seven
of 86 (8.1%) ethambutol-resistant strains and 3/52 (5.8%)
ethambutol-susceptible isolates carried an embB406 mutation.
However, a low frequency of mutations embB497 and
embB406 (≤6%) has been reported in ethambutol-resistant
strains by a limited number of studies.
8,10,31 A recent study,
which analysed all variations in the entire embCAB operon of
ethambutol-resistant isolates without an embB306 mutation,
showed that 10/34 (29.4%) non-embB306-mutated
ethambutol-resistant isolates carried embB497 mutations and
8/34 (23.5%) carried embB406 mutations,
29 while our results
showed 14/39 (35.9%) and 6/39 (15.4%), respectively. The high
proportion of embB497 and embB406 mutations that occurred
in ethambutol-resistant isolates lacking an embB306 mutation
in our study indicates the importance of embB497 and
embB406 mutations as additional hotspots to embB306 for the
rapid detection of ethambutol resistance using molecular
assays, especially in Henan, China. Although embB406 mutations
had been detected in ethambutol-susceptible isolates in two
previous studies,
13,31 embB497 mutations have not been found
in ethambutol-susceptible strains until now.
8,10,13,29,32 The
reason may be that embB497 mutations are located out of the
common region for detecting embB306 mutations and such
regions were not examined by many existing studies.
Similar to the ﬁnding in embB306 mutants, discordant
ethambutol susceptibility of embB497 mutants with identical
genetic background was also observed. Pair 3 isolates (isolate
21 versus isolate 108) sharing an identical VNTR-16 genotype
and sole embB497 mutation (CAG CGG) showed different
drug susceptibility; isolate 21 is ethambutol resistant while
isolate 108 is ethambutol susceptible (Figure 1a and b). This
result reveals that the contradiction between ethambutol drug
susceptibility and embB497 mutation testing results is probably
related to other mutations occurring outside the embB gene in
the genome of embB497 mutants, and provides more evidence
that the development of full ethambutol resistance may
require certain mutations occurring at multiple genes and
embB497 is one such mutation site.
embB mutations and broad drug resistance
We observed that embB mutations among clinical MDR-TB
strains from Henan are common, with 100/138 (72.5%) of
MDR-TB isolates carrying at least one mutation. To determine
whether these 27 mutation types of embB are speciﬁc to drug
resistance, 22 pan-susceptible clinical M. tuberculosis isolates
from Henan patients were adopted as controls for the embB
coding region analysis. Among 22 pan-susceptible clinical
MDR-TB isolates, a single mutation at embB534 was detected
in one strain, which indicates that embB534 is not a speciﬁc
mutation in drug-resistant M. tuberculosis. Nonetheless, among
the 12 embB534 MDR mutants, only 2 carried a single
embB534 mutation; 10 of them had additional embB mutations
(Table 2). Regardless of the embB534 mutation, the percentage
of embB mutants among MDR-TB isolates is 71.0% (98/138), of
which 58.2% (57/98) harboured embB306 mutations. Our
results suggest that excluding embB534 mutations, all other
embB-speciﬁc mutations in our patient population (and not
simply limited to the most frequently documented embB306
mutation) may be candidate markers for the prediction of multi-
drug resistance and broad ﬁrst-line polydrug resistance.
Existing commercial line probe assays are directed at detect-
ing rifampicin or rifampicin and isoniazid mutations that are
associated with phenotypic resistance. A rapid molecular assay
that could predict polyresistance beyond MDR would be of signiﬁ-
cant utility to the diagnostic laboratory. Several studies show
that the combination of a limited number of mutation sites
can be applied to predict the drug resistance of M.
embB mutations in MDR-TB
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24,33 To assess the possibility of using only embB
mutations to predict drug resistance, we performed trend analy-
sis correlating any embB mutation and the number of ﬁrst-line
drug resistances. The statistically signiﬁcant association (x
2
for trend¼26.5, P,0.0001) between embB mutations and
resistance to increasing numbers of antituberculosis reagents
[33.3% (3/9) of two-drug-resistant isolates (isoniazid/rifampicin
resistant) carried embB mutations, 53.8% (28/52) of
three-drug-resistant isolates (isoniazid/rifampicin/streptomycin
resistant or isoniazid/rifampicin/ethambutol resistant) carried
embB mutations and 89.6% (69/77) of four-drug-resistant iso-
lates (isoniazid/rifampicin/ethambutol/streptomycin resistant)
carried embB mutations] strongly suggests that embB mutations
might be sensitive candidate markers for the prediction of con-
current resistance to isoniazid, rifampicin, streptomycin and
ethambutol in M. tuberculosis clinical isolates. Moreover, 83.1%
of these four drug-resistant isolates can be detected by sequen-
cing a short fragment (606 bp) of the embB gene, which covers
10 mutation sites at codons 306, 328, 330, 354, 406, 424,
439, 469, 497 and 508. While it is yet unproven why mutations
affecting embB-encoded arabinosyl transferases may predict
resistance to other drugs, this study supports the ﬁndings of
others that embB306 is a predictor of multidrug resist-
ance.
12,15,24 In addition, our ﬁndings may lead to the develop-
ment of a simple molecular test to rapidly identify isolates that
are likely to express resistance to four ﬁrst-line drugs in Henan,
China, based on only a limited number of embB mutations.
Further studies would be required to examine such a strategy
in clinical practice and in other geographic locations around
the world.
In conclusion, our results demonstrated the mutation charac-
teristics of the entire embB gene in clinical MDR-TB isolates, an
undertaking not previously reported from China. Our results
clearly suggest that the ethambutol resistance of M. tuberculosis
depends on concurrent multiple mutations in the genome and
that embB mutations alone are not sufﬁcient for the develop-
ment of full resistance to ethambutol. The three pairs of clinical
isolates identiﬁed with identical VNTR genotypes and matched
embB mutations but different ethambutol phenotypic suscepti-
bility warrants further study. Using genome-wide single nucleo-
tide polymorphism analysis of the three pairs of isolates, novel
mutations contributing to ethambutol resistance are likely to
be discovered.
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